Executive Summary

The Global Health and Infectious Diseases Research Center (GHIDRC) is envisioned as a multidisciplinary research and innovation hub dedicated to addressing the world’s most pressing infectious disease challenges. The Center’s overarching vision is to contribute to a future in which infectious diseases no longer compromise human health, development, and societal progress. Its mission is to generate high-quality scientific evidence, foster technological and programmatic innovation, build capacity among the next generation of researchers, and translate knowledge into evidence-informed policies and practices.

GHIDRC will combine advanced scientific inquiry with capacity building in low- and middle-income countries (LMICs), strong policy engagement and applied research programs across tuberculosis (including drug-resistant forms), HIV and co-infections, malaria, emerging infections (Ebola, COVID-19) and antimicrobial resistance (AMR). The Center aims to establish laboratories, training programs, structured fellowships and partnerships that accelerate research-to-policy translation.

Background & Rationale

Infectious diseases remain a major cause of morbidity and mortality worldwide. Tuberculosis, HIV/AIDS, malaria and several neglected tropical diseases disproportionately affect LMICs. Antimicrobial resistance (AMR) and the frequent emergence of novel pathogens (e.g. SARS-CoV-2, Ebola) highlight gaps in preparedness, surveillance and rapid research response — gaps GHIDRC is designed to address.

10.6M
Estimated TB cases (2022)
249M
Estimated malaria cases (2022)
AMR
Projected 10M deaths by 2050 (if unchecked)

Vision & Mission

Vision: GHIDRC envisages a world in which infectious diseases are effectively controlled through cutting-edge research, innovative solutions and equitable public-health interventions.

Mission: Generate impactful evidence, foster innovation, train the next generation of global-health researchers and translate evidence into policy and practice.

Strategic Objectives

1

Conduct high-quality, multidisciplinary research on infectious diseases.

2

Build capacity of local and global researchers through fellowships and mentorship.

3

Translate evidence into policy and practice to strengthen health systems.

4

Foster innovation in diagnostics, treatments and prevention.

5

Strengthen partnerships between academia, governments and communities.

Key Research Priorities

Thematic research priorities are listed below. Click a heading to reveal focal activities and research directions.

Priority areas focus on diagnostics, therapeutics and programmatic research to reduce incidence and improve outcomes, including drug-resistant forms.

  • Drug resistance: molecular characterization of resistance mechanisms; clinical trials of novel regimens for MDR/XDR-TB.
  • Diagnostics: validation of rapid, affordable molecular and point-of-care tests adapted to resource-limited settings.
  • Treatment outcomes: implementation research on adherence, retention, and health-system determinants of success.
  • Co-morbidities: studies on TB–HIV and TB–diabetes interactions and integrated care models.

Organizational Structure & Governance

GHIDRC governance ensures scientific excellence, transparency and strategic alignment through:

Board of Directors

Strategic oversight, major policy approvals and representation of academia, donors and civil society.

Scientific Advisory Council

Independent international experts advising on research priorities and quality assurance.

Executive Leadership

Director supported by deputies for Research, Capacity Building and Administration.

Implementation Plan & Activities

Phase I — Establishment (Years 1–2)
  • Infrastructure: laboratories, data systems, training facilities.
  • Pilot research: TB resistance surveillance, HIV/TB co-infection studies, COVID seroprevalence.
  • Fellowships & capacity-building workshops.
  • Operational set-up: governance, finance, ethics review.
Phase II — Scale-Up (Years 3–5)
  • Large-scale multidisciplinary studies and multicountry collaborations.
  • Major grant acquisition (NIH, EDCTP, Wellcome, Global Fund).
  • Policy engagement and systems strengthening.
  • Scale-up of training programs and regional research schools.
Core activities across phases
  • Research projects (basic, clinical, implementation science)
  • Training & mentorship
  • Knowledge dissemination (open access, conferences)
  • Community engagement & stakeholder dialogues

Partnerships & Collaboration

Local

Hospitals, universities, NGOs and community organisations for access, trials and uptake.

Regional

Africa CDC, WHO AFRO and regional research consortia for multicountry initiatives.

International

NIH, Wellcome Trust, Global Fund, Gates Foundation, EU research programmes.

Resource Requirements

Infrastructure & Equipment

Laboratories, containment, data & IT systems. Estimated core equipment: USD 2–3M.

Programs Budget

Pilot & scale research: estimated USD 2–4M per year depending on scope.

Staffing

Scientists (epi, microbiology, immunology), clinicians, lab techs, data scientists, policy experts.

Expected Outcomes & Impact

Monitoring & Evaluation

Key Indicators
  • Research productivity (publications, patents, completed projects)
  • Training outputs (fellows, workshops)
  • Partnerships (MOUs, joint grants)
  • Policy influence (adopted briefs, guideline updates)
Reporting
  • Quarterly progress reports
  • Annual comprehensive report
  • Periodic external evaluations
  • Stakeholder feedback mechanisms

Conclusion

Establishing GHIDRC is a timely and transformative step to address persistent and emerging infectious disease threats. By integrating research, capacity building, innovation and policy translation, GHIDRC will strengthen regional and global health security.

Contact

Address: Avenue Dr Lurhuma, Quartier Nyakaliba, Commune de Kadutu, Ville de Bukavu, Sud-Kivu, DRC

Email: cele.kyambis@istmbukavu.org

Phone: +243 997 769 126

Contact GHIDRC